| Molecular Formula | C23H17FN6O |
| Molar Mass | 412.42 |
| Density | 1.40 |
| Melting Point | >250°C (dec.) |
| Appearance | Form Solid, color Pale Yellow to Light Yellow |
| pKa | 13.82±0.46(Predicted) |
| Storage Condition | -20°C Freezer, Under inert atmosphere |
| Use | Application Capmatinib is an oral proto-oncogene c-Met inhibitor (also known as hepatocyte growth factor receptor (HGFR)) with potential anti-tumor activity. Capmatinib are widely used in clinical trials to study melanoma, gliosarcoma, solid tumors, colorectal cancer and liver injury. |
| 1mg | 5mg | 10mg | |
|---|---|---|---|
| 1 mM | 2.425 ml | 12.124 ml | 24.247 ml |
| 5 mM | 0.485 ml | 2.425 ml | 4.849 ml |
| 10 mM | 0.242 ml | 1.212 ml | 2.425 ml |
| 5 mM | 0.048 ml | 0.242 ml | 0.485 ml |